Trial Profile
An open-label extension study following the RIN-1 study to investigate the efficacy of rituximab against a relapse of neuromyelitis optica
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Neuromyelitis optica
- Focus Adverse reactions
- Acronyms RIN-2
- Sponsors Zenyaku Kogyo
- 29 Mar 2019 Status changed from recruiting to completed.
- 29 Oct 2015 New trial record